Skip to main content

Table 2 Impact of cumulative ginseng intake on baseline CERAD total and MMSE-DS scores

From: Effects of lifetime cumulative ginseng intake on cognitive function in late life

 

Cumulative ginseng intake

F value for ANOVA

F(2, 6420)

Post hoca

F value for ANCOVAb

F(2, 4762)

Post hoca

Baseline neuropsychological tests

No use

(N = 5745)

Low use

(< 5 years)

(N = 491)

High use

(≥ 5 years)

(N = 186)

CERAD total score

60.2 ± 14.9

64.8 ± 12.3

68.1 ± 10.8

47.049*

0 < 1 < 2

  

62.3 ± 13.6

65.9 ± 11.7

68.5 ± 10.7

  

3.978**

0 < 2

MMSE-DS score

25.2 ± 4.2

26.3 ± 3.1

27.0 ± 2.2

32.825*

0 < 1, 0 < 2

  

25.9 ± 0.043

26.1 ± 0.139

26.2 ± 0.221

  

1.174

  1. Data shown as mean ± standard deviation for analysis of variance (ANOVA), adjusted mean ± standard error for analysis of covariance (ANCOVA)
  2. CERAD Consortium to Establish a Registry for Alzheimer’s Disease, MMSE-DS Mini-Mental State Examination for dementia screening
  3. *p < 0.001; **p = 0.019
  4. aPost-hoc analysis using Bonferroni; 0, 1, and 2 denote no-users, low ginseng intake group (< 5 years), and high ginseng intake group (≥ 5 years) respectively
  5. bANCOVA adjusted for age, sex, years of education, socioeconomic status, body mass index, smoking (pack-years), alcohol intake (units in lifetime), presence of hypertension, stroke history, Korean version of Geriatric Depression Scale, Cumulative Illness Rating Scale, and presence of APOE e4 allele